Who Usually Gets Multifocal Motor Neuropathy (MMN)?
At a Glance
Multifocal motor neuropathy is extremely rare and most often begins in middle-aged men, commonly in the 40s or 50s. It can affect other adults too, and age or sex cannot confirm or rule out the diagnosis.
Multifocal Motor Neuropathy (MMN) is a very rare nerve condition that predominantly affects middle-aged men [1][2]. If you are wondering whether you or a loved one fit the “typical profile,” the most common person to develop MMN is a man in his 40s or 50s. However, these are patterns seen in groups of patients, not a test of whether you have the condition. MMN can affect people outside of these typical demographics, and age or sex alone cannot be used to confirm or rule out a diagnosis [1].
How Rare is MMN?
MMN is considered an extremely rare disease. Studies across different countries estimate that it affects roughly 0.4 to 1.9 people per 100,000 [3][4][5]. To put this in perspective, in a city of one million people, only about 4 to 19 individuals would be expected to have this condition based on these estimates [3][5]. This extreme rarity means many primary care doctors, and even some general neurologists, may never see a case of MMN during their careers.
Who is Most Often Diagnosed?
When researchers look at groups of people diagnosed with MMN, clear demographic patterns emerge. It is important to remember that these statistics do not explain why an individual develops MMN, nor do they predict your personal disease course or treatment response.
- Age of Onset: Symptoms most frequently begin in middle adulthood. Many studies report the average or median age when symptoms first appear is roughly between 40 and 44 years old [3][4]. While it most commonly starts in a person’s 40s or 50s, cases have been reported across a wider adult age range, often noted from the 20s through the 70s [1]. Childhood onset is considered exceptionally rare [1][6].
- Sex Distribution: Available studies report more diagnoses in men than women. Research from multiple countries shows that men are roughly twice as likely to develop the condition. For example, large surveys and registries report male-to-female ratios ranging from about 1.9-to-1 up to 2.3-to-1 [3][7].
- Other Factors: Currently, there are no established lifestyle, environmental, or genetic risk factors that are proven to cause MMN. Most cases are sporadic, meaning they occur randomly without being passed down through families, though early research continues to explore if there are genetic susceptibilities [8]. Ordinary arm or hand use is not known to cause MMN, so you should not feel that everyday activities or hobbies caused the condition.
How is MMN Identified?
Because MMN shares symptoms with more common nerve and muscle disorders, diagnosis often requires specialized evaluation. MMN is typically evaluated based on a specific pattern of weakness (often worse on one side or starting in one limb, particularly the hands or arms) with preserved sensation (normal ability to feel touch and pain). Neurologists confirm this using a physical examination and specialized electrodiagnostic testing, such as nerve conduction studies or an electromyogram (EMG), to look for specific nerve blockages.
(Note: If you experience sudden, rapidly worsening weakness, or any new trouble with swallowing or breathing, seek prompt medical assessment. While MMN is typically slowly progressive, these specific symptoms could indicate a different condition or a medical emergency.)
Common questions in this guide
Who is most likely to develop multifocal motor neuropathy?
Is MMN more common in men than women?
Can younger people or children develop MMN?
Is multifocal motor neuropathy inherited or caused by lifestyle?
How is MMN diagnosed if it is so rare?
How common is multifocal motor neuropathy?
Related questions
Show more
Get notified when new evidence is published on Multifocal motor neuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a.
Maeda H, Ishii R, Kusunoki S, Chiyonobu T
Brain & development 2020; (42(1)):88-92 doi:10.1016/j.braindev.2019.08.013.
PMID: 31522790 - 2
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry.
Stangel M, Gold R, Pittrow D, et al.
Therapeutic advances in neurological disorders 2016; (9(3)):165-79 doi:10.1177/1756285616629869.
PMID: 27134672 - 3
Multifocal motor neuropathy in Japan: A nationwide survey on prevalence, clinical profiles, and treatment.
Aotsuka Y, Misawa S, Suichi T, et al.
Muscle & nerve 2024; (70(5)):1027-1033 doi:10.1002/mus.28251.
PMID: 39253889 - 4
Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment.
Löscher WN, Oberreiter EM, Erdler M, et al.
Journal of neurology 2018; (265(12)):2834-2840 doi:10.1007/s00415-018-9071-9.
PMID: 30259176 - 5
Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia.
Park SB, Li T, Kiernan MC, et al.
Muscle & nerve 2022; (66(5)):576-582 doi:10.1002/mus.27698.
PMID: 36054471 - 6
IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset.
Budding K, Bos JW, Dijkxhoorn K, et al.
Journal of neuroinflammation 2024; (21(1)):100 doi:10.1186/s12974-024-03090-y.
PMID: 38632654 - 7
Diagnosis and Management of Multifocal Motor Neuropathy in the United Kingdom: A Multicentre Survey.
Rajabally YA, Englezou C, Cluett G, et al.
Journal of the peripheral nervous system : JPNS 2025; (30(2)):e70018 doi:10.1111/jns.70018.
PMID: 40210218 - 8
High-resolution mapping identifies HLA class II associations with multifocal motor neuropathy.
Bos JW, Otten HG, Herraets IJT, et al.
Neurobiology of aging 2021; (101()):79-84 doi:10.1016/j.neurobiolaging.2021.01.014.
PMID: 33582569
This page about who typically develops MMN is for informational purposes only and does not constitute medical advice. Age, sex, symptoms, and test results should be interpreted by a qualified neurologist.